23 April 2021 : Original article
A Single-Center Experience with Lung Transplants During the COVID-19 Pandemic
Wojtek Karolak1ABE, Elżbieta Woźniak-Grygiel2CE, Monika Łącka3BC, Jacek Wojarski1BG, Salma Ali Addo4EF, Adith Kumaravel4EF, Salin Khan4EF, Reema Shinde4EF, Ikram Mukhtar Nuur4EF, Feven Kifle Reta4EF, Jan Rogowski1G, Ewa Jassem4EG, Krystyna Pastwa4F, Aleksandra Pałasz1B, Nikodem Ulatowski1B, Sławomir Żegleń24ADG*DOI: 10.12659/AOT.929946
Ann Transplant 2021; 26:e929946
Table 2 Recipient characteristics.
| Characteristics | Lung transplant 2019 before COVID-19N=12Mean±SD/n (%) | Lung transplant 2020 during COVID-19N=16Mean±SD/n (%) | p |
|---|---|---|---|
| 50.1±12.8 | 50.6±14.5 | 0.6197 | |
| Female | 4 (33.3%) | 6 (37.6%) | 0.8143 |
| Male | 8 (66.6%) | 10 (62.5%) | 0.8227 |
| COPD | 8 (66.6%) | 5 (31.3%) | 0.0638 |
| CF | 1 (8.3%) | 2 (12.5%) | 0.7220 |
| IPF | 2 (16.6%) | 2 (12.5%) | 0.7588 |
| IPAH++++ | 1 (8.3%) | 3 (18.8%) | 0.4322 |
| EAA | 0 (0.0%) | 1 (6.3%) | 0.3758 |
| UIP | 0 (0.0%) | 2 (12.5%) | 0.2037 |
| COVID | 0 (0.0%) | 1 (6.3%) | 0.3758 |
| ECMO | 5 (41.6%) | 12 (75.0%) | 0.0734 |
| Off pump | 6 (50.0%) | 2 (12.5%) | 0.0297 |
| Conversion to ECMO | 1 (8.3%) | 2 (12.5%) | 0.7220 |
| COVID-19 – corona virus disease – 2019; COPD – chronic obstructive pulmonary disease; CF – cystic fibrosis; IPF – idiopathic pulmonary fibrosis; IPAH – idiopathic pulmonary arterial hypertension; EAA – extrinsic allergic alveolitis; UIP – usual interstitial pneumonia; COVID – COVID-19 related fibrosis; ECMO – extra-corporeal membrane oxygenation; SD – standard deviation. | |||